American Association for Cancer Research

sorry, we can't preview this file

cir-22-0197_supplementary_figures_suppsf1-sf11.docx (1.25 MB)

Supplementary Figures from NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy

Download (1.25 MB)
journal contribution
posted on 2023-04-04, 01:45 authored by Tongtong Lin, Liang Hu, Fan Hu, Kun Li, Chao-Yu Wang, Li-Juan Zong, Ya-Qian Zhao, Xiaotao Zhang, Yan Li, Yang Yang, Yu Wang, Chun-Yi Jiang, Xuefeng Wu, Wen-Tao Liu

Supplementary Figures 1-11


National Natural Science Foundation of China (NSFC)

Basic Research Program of Jiangsu Province

Major Project of " Science and Technology Innovation Fund" of Nanjing Medical University

Key R&D Program (Social Development) Project of Jiangsu Province

Nanjing special fund for health science and technology development



Oxaliplatin is an antineoplastic agent frequently used in the treatment of gastrointestinal tumors. However, it causes dose-limiting sensorimotor neuropathy, referred to as oxaliplatin-induced peripheral neuropathy (OIPN), for which there is no effective treatment. Here, we report that the elevation of neutrophil extracellular traps (NET) is a pathologic change common to both cancer patients treated with oxaliplatin and a murine model of OIPN. Mechanistically, we found that NETs trigger NLR family pyrin domain containing 3 (NLRP3) inflammasome activation and the subsequent release of IL18 by macrophages, resulting in mechanical hyperalgesia. In NLRP3-deficient mice, the mechanical hyperalgesia characteristic of OIPN in our model was reduced. In addition, in the murine model, treatment with the IL18 decoy receptor IL18BP prevented the development of OIPN. We further showed that eicosapentaenoic acid (EPA) reduced NET formation by suppressing the LPS–TLR4–JNK pathway and thereby abolished NLRP3 inflammasome activation and the subsequent secretion of IL18, which markedly prevented oxaliplatin-induced mechanical hyperalgesia in mice. These results identify a role for NET-triggered NLRP3 activation and IL18 release in the development of OIPN and suggest that utilizing IL18BP and EPA could be effective treatments for OIPN.

Usage metrics

    Cancer Immunology Research





    Ref. manager